420 with CNW — Oklahoma Supreme Court Shoots Down Two Challenges to Cannabis Legalization Measure

Last week, the Oklahoma Supreme Court rejected a pair of legal challenges against a cannabis legalization proposal. The court afforded the petitioners a small window to request for a rehearing as it prepares to make a final ruling in the coming week on whether the proposal can be brought before voters this year.

The deadline to send in challenges against the proposed amendment to the constitution closed earlier in the week. Four challenges were filed, including two concerning the language of the ballot title, and two that dealt with signature certification, which were shot down by the court.

One of the rejected challenges came from Mike Reynolds, a former legislator from Oklahoma, who claimed that a state law that was recently enacted on election integrity made it almost impossible to review signatures. In its ruling, the court stated that Reynolds had been able to access the petition after he had filled out his application as per the statute, noting that his request for more days to challenge the proposal after he’d reviewed the signatures would violate the plain language and legislative intent of the statute.

The other dismissed challenge was made by Paul Tay, a controversial marijuana activist who alleged that signatures gathered on sovereign Indian land weren’t valid. He made a similar complaint against a legalization measure led by another campaign In its ruling, the court stated that it had lost patience with the activist, noting that he had a history of filing original proceedings, the majority of which had no legitimate basis legally.

In addition to the response, the Oklahoma Supreme Court revoked Tay’s pauperis status, which had enabled him to file complaints in the past without paying any fee.

Oklahomans for Sensible Marijuana Laws (OSML) submitted more signatures than required to qualify its legalization initiative in July. The organization also accepted revisions to the ballot title language from the state’s attorney general before the Office of the Secretary of State certified the signatures in August.

In a statement, Yes on 820’s campaign director, Michelle Tilley, stated that the group had been confident that the court would reject any frivolous complaints, noting that the court had done that by dismissing the complaints filed during the protest period.

The remaining complaints, include one which argues that the ballot title’s language is misleading because it doesn’t sufficiently inform voters about policy impacts of the measure. For example, the lack of disclosure about provisions for decriminalization for individuals aged 21 and under and firearm-related implications makes the title misleading.

The other complaint was made by Jed Green, a marijuana activist who also maintained that there were omissions in the title of the ballot.

If the ballot measure is cleared by the top court in the state, voters could have a chance to approve it and pave the way for licensed cannabis companies similar to the likes of Cannabis Strategic Ventures Inc. (OTC: NUGS) to set up shop in Oklahoma and address the needs of consumers there.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Survey Finds Most Republicans Support Incremental Marijuana Policy Reforms

Most progressive measures in the United States have been pushed by Democratic lawmakers and supported by left-leaning voters. Democrats were almost entirely responsible for the wave of cannabis reform that has swept across the country, with most left-leaning states now allowing some kind of legal marijuana market. However, a recent survey has revealed that attitudes toward cannabis prohibition and legalization are also changing on the other side of the political divide.

The survey found that voters who identify as Republican support various cannabis reform measures, including legalizing the controversial plant, expunging certain cannabis-related offenses from people’s records and allowing states to determine their own marijuana policies. The survey was commissioned by the National Cannabis Roundtable (NCR).

Survey results indicate that 76% of Republicans who responded said they supported noninterference by the federal government in state-legal cannabis markets, 56% supported expunging prior cannabis offenses in legal cannabis states, and 73% were in favor of treating cannabis businesses like other industries. These results came at a time when lawmakers are working feverishly to develop viable marijuana legislation before the end of the congressional calendar.

However, there is little likelihood of Congress passing federal marijuana reform before the session ends, and some stakeholders do not believe that Republicans support anything besides cannabis banking legislation. In the survey, 65% of Republicans said they supported measures that would finally allow cannabis businesses to access banking services.

Several prominent Democratic lawmakers, including Senate Majority leader Chuck Schumer, Senator Cory Booker and Senator Ron Wyden, have vowed not to pass cannabis banking measures before comprehensive legalization.

Although the legislation would finally allow cannabis businesses to access cashless payments and capital, Schumer believes passing it first would place corporate interests over social equity. He recently unveiled a comprehensive federal cannabis bill that would legalize the plant at the federal level and expunge past nonviolent cannabis offenses from people’s records. On the other hand, proponents of cannabis legalization argue that lack of access to banking services is exposing the cannabis industry to security risks and limiting its access to capital.

Banking institutions have stayed away from the state-legal cannabis industry ever since its inception, forcing businesses in the sector to rely on cash-only transactions. Lawmakers included banking protections in a package of policy changes called SAFE Banking Plus in an effort to pass some kind of cannabis legislation before the current legislative session elapses. It has social-equity provisions as well as protections for banks that serve businesses in the cannabis sector.

If these reforms are finally passed into law, the operating environment for industry companies such as Flora Growth Corp. (NASDAQ: FLGC) will improve a great deal as a uniform federal law on marijuana comes into force.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – REZYFi Inc. Stands Distinct with Service to State-Licensed Cannabis Industry, Proprietary Technology

REZYFi, a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses, is one of the first mortgage bankers of its kind in the United States. The company is leveraging its position in a market where most traditional lenders remain diffident to serve the state-licensed cannabis industry. “Through its two wholly owned subsidiaries – REZYFi Lending and ResMac Inc. – REZYFi is targeting licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financing,” reads a recent article. “REZYFi is demonstrating its corporate strengths within the market through experience, a network of independent brokers, and proprietary technology through both subsidiaries… Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers – with training that has already commenced for network members to familiarize them with the company’s new service offerings. Through its proprietary automated/machine learning technology, REZYFi shortens loan processing timeframes and increases efficiency, allowing it to operate its legacy business at staffing levels meaningfully below its competition.”

To view the full article, visit https://cnw.fm/fZShH

About REZYFi Inc.

REZYFi is a cannabis-focused mortgage origination and specialized financing company in the U.S. The company originates, structures and invests in first mortgage loans and alternative structured financings secured by commercial and residential real estate properties. For more information, visit the company’s website at REZYFi.com.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://cnw.fm/REZY

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Advanced Container Technologies Inc. (ACTX) CEO, Inventor of GrowPods Share Insight on the Future of Farming

Advanced Container Technologies (OTC: ACTX) was featured in a recent episode of “Gamechangers LIVE.” Doug Heldoorn, CEO of ACTX, the exclusive U.S. distributor of GrowPods — self-contained, hydroponic “micro-farms,” and Shannon Illingworth, the inventor of GrowPods, joined the podcast to discuss the future of farming in America and the world. According to a recent Wall Street Journal article, the global food supply is in critical condition. The Guardian further projects that the world’s population is expected to reach nearly 10 billion by 2050 and will require a 70% increase in global food production but speculates today’s food systems are not ready and that the answer to mounting challenges may be in hydroponic or vertical farming. “GrowPods can give traditional farmers a niche to grow high-quality produce year-round,” Illingworth said in the interview with Sergio Tigera, host of Gamechangers LIVE. “Because GrowPods can be located virtually anywhere, food can quickly go from farm to the table, dramatically reducing transportation time, so food stays fresh, healthy and nutritious.”

To view the full press release, visit https://cnw.fm/wk3Jv

About Advanced Container Technologies Inc.

Advanced Container Technologies is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer(R), that store and grind pharmaceuticals, herbs, teas and other solids or liquids. For more information, visit the company’s website at www.AdvancedContainerTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to ACTX are available in the company’s newsroom at https://cnw.fm/ACTX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — US Court of Appeals Rules Marijuana’s Federal Scheduling Is Irrational, Not Unconstitutional

A recent ruling handed down by the U.S. Court of Appeals for the Second Circuit states that the decision by the federal government to classify marijuana under Schedule I of the Controlled Substances Act is not unconstitutional but is plausibly irrational. The Controlled Substances Act was approved by the 91st United States Congress and signed into law by former President Richard Nixon. It became effective May 1, 1971. Schedule I substances under this act are, by definition, substances that currently have no accepted medical use in treatment and have a high potential for abuse.

Drugs classified under this schedule include LSD, heroin, peyote, methaqualone, ecstasy and cannabis.

The case in question is United States of America vs. Green.

During the trial, the defendants argued that cannabis’ scheduling under the Controlled Substances Act had no rational basis because marijuana did not meet the statutory criteria for inclusion in its current classification.

The U.S. Court of Appeals judges rejected this argument, stating that the scheduling criteria of the Controlled Substances Act was to a large extent irrelevant to their constitutional review, as the rational basis test only asked if Congress had any plausible basis for including cannabis under Schedule I. They added that while there were other conceivable considerations that could have been the motive behind marijuana’s scheduling, its classification did not violate equal protection rights or due process.

While the judges did acknowledge that the defendants’ argument that it was irrational for the federal government to maintain that cannabis had no accepted medical rule, they maintained that this was not enough to compel the court to rule marijuana’s current classification as unconstitutional.

In their conclusion, the judges stated that the defendants needed to do more beside simply demonstrating that the legislature’s assumptions about marijuana were irrational.

Paul Armentano, deputy director of NORML, stated that while the court’s decision wasn’t unanticipated, it was disappointing. Armentano acknowledged that the ruling was consistent with those of other federal courts that had in a similar way declined to nullify marijuana’s Schedule I classification as unconstitutional.

Prior rulings opined that the rational basis review did not permit the federal courts to second guess decisions made by Congress.

He highlighted that judges had repeatedly ruled that it was the responsibility of federal legislators and not the courts to rescind the federal prohibition of cannabis. Armentano added that instead of expecting relief from federal courts, citizens needed to continue pressuring their elected officials to annul this destructive and admittedly “irrational” policy.

Needless to say, pressure is mounting at various levels to see marijuana policy reform enacted, and such pressure could pave the way for the widespread use of grow pods in the fashion of those made by Advanced Container Technologies Inc. (OTC: ACTX) as more people opt for sustainably grown cannabis and other produce.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Florida Judge Slams State for Slow Medical Marijuana Licensing Process

Florida legalized medical cannabis in 2014 and began allowing qualified patients to access non-smoked, low-THC cannabis in January 2015. Another measure passed in 2017 created a more comprehensive regulatory framework for Florida’s medical cannabis industry. It also required that the state Department of Health issue new medical cannabis licenses as the number of qualified patients increased.

However, despite the fact that Florida now has more than 700,000 medical marijuana patients and should have granted another 22 medical marijuana licenses, regulators are yet to do so.

Earlier this month, an appeals judge chastised state health officials for the slow medical marijuana licensing process. Florida should have doubled its medical cannabis dispensers to keep up with the growing number of patients, the judge said, but the slow licensing process has left potential applicants “understandably frustrated.”

Florida First District Court of Appeals Judge Ross Bilbrey wrote in a ruling for an MMJ licensing case that nearly five years after lawmakers issued the emergency rule, Florida’s medical cannabis licensing window is still closed. Alongside two other justices, Bilbrey upheld a lower court’s decision to dismiss a lawsuit from an applicant seeking a medical marijuana treatment center license.

Bilbrey noted that the Department of Health’s failure to reopen the license application window had left the defendant understandably frustrated. News Service of Florida reports that Florida currently has 22 medical marijuana operators, nearly half of the operators the state needs to cater to the swelling medical marijuana market. But since Governor Ron DeSantis’ administration took office, the application window has remained closed, leaving hopeful applicants hanging in limbo as they wait for the government to move forward.

Although the governor’s office said litigation over the 2017 law for the license application was the reason for the delay, the statute was finalized by a state Supreme Court decision last year. During a trial involving MedPure LLC more than two years ago, a Department of Health lawyer told Bilbrey that the health agency had halted the licensing process due to a lawsuit that was filed against the 2017 statute by Tamba-based company Florigrown.

Ultimately, the Supreme Court threw out the lawsuit and upheld the 2017 law. Consequently, Bilbrey wrote that he understood why applicants such as Louis Del Favero Orchids Inc., the organization behind the lawsuit that was dismissed by a lower court, are frustrated. They have waited with bated breath for the state to open the licensing process to no avail.

Bilbrey and his colleagues may have sided with the Department of Health and upheld the lower court’s decision, but he called out regulators for dragging their feet in opening the medical marijuana licensing process. The judge has also questioned Department of Health officials on the license application delay on several occasions.

Such progressive court judgments are needed to nudge policymakers in different jurisdictions where licensed companies such as American Cannabis Partners operate to set up the necessary systems pivotal to meeting the needs of different consumer segments.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) 7x YOY Revenue Growth for H1 2022 Affirms Hyper Growth

H1 2022 revenue increased to ~$15.0 million, up 604% from H1 2021 and 117% from H2 2021, driven by House of Brands
Gross Profit increased to ~$7.0 million, up 547% compared to H1 2021 and 363% compared to H2 2021
Company reaffirms its 2022 revenue guidance to range between $35.0 million – $45.0 million, indicating approximately 300% – 400% projected revenue growth from 2021

In August, Flora (NASDAQ: FLGC) released its financial and operating results for the six months that ended June 30, 2022 (https://cnw.fm/4Oeqb). As an internationally focused cannabis company, the organization’s management acknowledged how challenging the current global cannabis environment is. However, it also lauded the team’s ability to deliver on plan and the overall company’s focus on its goals for the current financial year.

The release indicated that Flora posted total revenue of $14.9 million for the first half of the 2022 fiscal year (“H1 2022”), 7x year-over-year (“YOY”) growth, and 2x sequential growth. This growth was attributed to Flora’s House of Brands division, which include the acquisitions of Vessel and JustCBD. The performance, according to the company’s Chairman and Chief Executive Officer (“CEO”), Luis Merchan, delivered on the company’s promise to double its revenue compared to H2 2021.

“In the first half of 2022, Flora delivered on its promise to double revenue compared to the second half of 2021, and we expect to maintain that trajectory to deliver our full-year guidance as a result of continued growth in our House of Brands, the launch of several new brands in the United States and the commencement of sales in our Commercial Wholesale and Life Sciences business,” noted Mr. Merchan (https://cnw.fm/mMVpx).

The company kicked off 2022 with the integration of both Vessel and JustCBD. It also saw the bolstering of its human resources following the appointment of former Director of Cannabis for the Florida Department of Agriculture and Consumer Services, Holly Bell, as the Vice President of Regulatory Affairs. Flora also signed a distribution agreement with Giant OTG Management to offer access to JustCBD products in airports within the United States and strengthened its European presence by opening an office in London.

All these investments, and more, have paid off significantly for the company, and its management believes that it has achieved a path to profitability. The company has reaffirmed its 2022 revenue guidance to range between $35 million and $45 million, representing growth of approximately 300% to 400% over 2021.

“With all three of our core pillars generating revenue in the second half of 2022, continued gross margin expansion and a focus on streamlining operating expenses- we believe we have a path to profitability that few global cannabis companies can achieve in this difficult environment,” noted Mr. Merchan. “The execution of our key initiatives is a testament to our team’s ability to deliver on plan. We will continue to execute as we focus on profitability and long-term value creation,” he added (https://cnw.fm/mMVpx).

Flora H1 2022 revenue increased to ~$15.0 million, up 604% from H1 2021 and 117% from H2 2021, driven by House of Brands. Gross Profit increased to ~$7.0 million, up 547% compared to H1 2021 and 363% compared to H2 2021. The company reaffirms its 2022 revenue guidance to range between $35.0 million – $45.0 million, indicating approximately 300% – 400% projected revenue growth from 2021.

Going forward, the company is set to benefit from the addition of strategic management players in its team, such as Elshad Garayev, the new Chief Financial Officer (“CFO”), and Brandon Konigsberg, who serves on the Board of Directors as Chair of the Audit Committee and as a member of the Compensation Committee.

Flora has also entered into an agreement with Pharma Indigena Misak Manasr Sas (“Manasr”), the largest indigenous tribe in Colombia, to commercialize and sell cannabis products domestically and internationally in partnership with the Misak people. This will further accentuate the company’s performance, particularly given the favorable regulatory tailwind that the company is experiencing already in Colombia. It will also play an integral role in achieving the projected revenue goals for the current financial year.

In addition, a recent Zacks SCR report (https://cnw.fm/kJgU2) lists the following key positives for the company in light of their release:

1H22 augers well for meeting targets
benefiting from cost advantages
favorable regulatory environment

For more company information, visit the company’s website at www.FloraGrowth.com.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

REZYFi Inc. Addresses Loan Needs of Growing Cannabis Industry Through Subsidiary Companies: REZYFi Lending and ResMac Inc.

The global cannabis market is expected to reach $33 billion by 2025, driven by legality and regulation within the market
REZYFi is servicing the needs of both traditional and non-traditional consumers and businesses
Company targets licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing
REZYFi’s management team is leveraging its extensive industry experiences in real estate, finance and cannabis to pursue company objectives

The cannabis industry has experienced significant growth in recent years due to the expanding legalization and interest from venture capital firms. This growth is not only being seen in the United States but worldwide. Global cannabis sales are expected to increase from $13.4 billion in 2020 to $33 billion by 2025 (https://cnw.fm/oV6bG). Legality and regulation are key forces that drive this market in the United States, but banking continues to be a challenge as cannabis companies cannot legally access traditional banking services. The Federal Reserve began raising interest rates in March 2022, which makes it even harder for cannabis companies to raise capital and fuel future growth.

As a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses, REZYFi is targeting markets that include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based and project-specific financings – like solar installations and real estate development projects. The company is positioned as one of the first cannabis mortgage bankers in the United States, an arena where most traditional lenders remain reticent to serve state-licensed cannabis companies.

To overcome many of the challenges that the companies in the cannabis industry face, REZYFi plans to utilize its corporate strengths to facilitate growth, namely experience, a network of independent brokers, and proprietary technology. REZYFi’s experience comes from a management team with significant expertise that spans a wide range of real estate and financial sectors. This team also has extensive experience in the cannabis and hemp industries, which they will leverage as the company navigates the ever-changing cannabis industry landscape.

Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers, allowing the company to train network members on its new service offerings. REZYFi believes this network is a vital asset as it moves forward in an industry where other firms are abandoning the cause. These strengths, coupled with REZYFi’s proprietary automated/machine learning technology, can shorten the loan processing timeframes and increase overall efficiencies. This allows REZYFi to operate its legacy business at staffing levels meaningfully below its competitors.

REZYFi operates through its two wholly owned subsidiaries from its base of operations in Miami, Florida. The first, REZYFi Lending, primarily addresses the emerging real estate-related financing opportunities within the targeted industry. The second, ResMac Inc., is the company’s traditional mortgage origination, correspondent and servicing option. These subsidiaries are licensed to serve 34 states, and the company plans to expand to the remaining 16 states later in 2022.

For more information, visit the company’s website at www.REZYFi.com.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://cnw.fm/REZY

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Provide Bioavailable Oral Treatment for Hypertension, Mitigate Effects of High Blood Pressure

Lexaria is a biotechnology company pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”)
The company has developed the patented DehydraTECH(TM) drug delivery technology, which has been shown to deliver more API at a faster rate than controls
Lexaria’s DehydraTECH pipeline includes DehydraTECH-CBD for the treatment of hypertension
Through pre-clinical studies, DehydraTECH-CBD has been shown to decrease systolic blood pressure among hypertensive volunteers
The company intends to file an Investigational New Drug (“IND”) application and has already received confirmation that the FDA agrees with its proposed abbreviated pathway under section 501(b)(2)

Oral delivery remains the preferred route of administering drugs among cooperating and conscious patients. But some drugs do not have the desired physicochemical and pharmacokinetic characteristics that favor oral administration, an issue that is linked to poor bioavailability. This has often led to the use of other routes or prompted the administration of higher doses, with the latter causing toxicity concerns and risks tied to erratic and unpredictable responses. These challenges, coupled with the fact that more than 90% of therapeutic compounds are known to possess oral bioavailability limitations, have necessitated research that explores ways to enhance oral drug bioavailability (https://cnw.fm/5fM38).

The research has been spearheaded by scholars and scientists as well as companies such as Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms. A biotechnology company focusing its attention and resources on pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”), Lexaria developed the patented DehydraTECH(TM) drug delivery technology.

Designed to be incorporated into the formulation and manufacturing process of existing or new topical and ingestible products, the technology works with existing physiological systems to facilitate enhanced and more rapid absorption of drugs into the bloodstream and cells. In fact, the company has evidenced, through in vivo, in vitro and pre-clinical testing, that DehydraTECH delivers more API at a faster rate than controls, enabling more effective drug absorption. The testing has so far involved APIs such as cannabidiol (“CBD”), PDE5 inhibitors, antiviral drugs, and nicotine, each at different stages of product development.

This DehydraTECH pipeline, Lexaria says, is addressing severe unmet patient needs. Its DehydraTECH-CBD compound, for example, specifically targets the hypertension space; in the U.S., about 47% of adults, or 116 million people, have hypertension, with only about 24% having the condition under control (https://cnw.fm/xssBQ), while globally, hypertension affects more than 1 billion people, or about 30% of the adult population (https://cnw.fm/mKSVw).

A person is considered hypertensive if and when their systolic blood pressure (when the heart is beating) exceeds 130 mmHg or their diastolic blood pressure (when the heart is at rest) is greater than 80 mmHg or if they are on hypertension medication. This heightened pressure has several consequences, including the fact that it makes arteries less elastic, effectively damaging them. This damage, in turn, decreases the blood flow and oxygen to the heart, leading to heart disease. The decreased blood flow also increases the risk of stroke.

In extreme cases, hypertension causes death. In 2020, over 670,000 people died from hypertension in the United States, according to the Centers for Disease Control (“CDC”). Globally, the World Health Organization (“WHO”) reports, 7.5 million people die from high blood pressure annually (https://cnw.fm/sz7n4). Unfortunately, some of these deaths occur among patients who may not have noticed any symptoms, leading to the recognition of hypertension as a “silent killer.” The good news? There are several approved blood pressure medications, with scores still under development or evaluation, including Lexaria’s DehydraTECH-CBD.

In its human pre-clinical studies, Lexaria has shown that DehydraTECH delivers 317% more CBD to the bloodstream. Its HYPER-H21-1 study demonstrated that DehydraTECH-CBD results in a rapid and sustained drop in blood pressure, particularly systolic pressure and especially in stage 2 hypertensive volunteers (those whose systolic pressure exceeds 140 mmHg). In addition, the company separately showed, through its HYPER-H21-2 study, that its drug candidate results in a 23% average reduction in overnight blood pressure and reduces arterial stiffness, while its HYPER-H21-3 study demonstrated attenuated pulmonary artery systolic pressure by -5 mmHg (https://cnw.fm/nUKSQ).

Motivated by the positive results, Lexaria is marching toward filing an Investigational New Drug (“IND”) application, having already received confirmation from the U.S. Food and Drug Administration (“FDA”) that the agency had agreed with the company’s proposal to pursue the 505(b)(2) new drug application (“NDA”) abbreviated regulatory pathway (https://cnw.fm/WPQV2).

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Why Marijuana Is Growing in Popularity While Cigarettes Lose Out

Despite being prohibited in most areas for the past couple of decades, cannabis has been the most-used drug in the world for quite a while. As of July 2022, an estimated 200 million people used cannabis across the globe. Legalization efforts have significantly increased access to the controversial plant, allowing millions to legally purchase and consume cannabis with no legal repercussions.

Dozens of American states, as well as territories around the world, now have legal cannabis markets. As a result, more people than ever are using cannabis, and one industry that has dominated the recreational drug space has begun to feel the heat. According to a pair of recent polls by Gallup, more Americans now smoke marijuana than smoke cigarettes. The surveys also provided more evidence of an ongoing reduction in the number of Americans who smoke cigarettes.

According to a August 2022 Gallup poll, 16% of the survey participants reported smoking marijuana compared to 12% in a similar poll from last year. Although Gallup noted that this increase was not statistically significant, it highlights a growing acceptance of cannabis in American society.

In addition, 11% of Americans who were surveyed in a different poll that was published in July said they had smoked tobacco cigarettes. In comparison, 16% of survey participants said they had indulged in a cigarette in the week in a 2021 poll. It is a significantly larger drop from the 45% of adults who admitted to smoking cigarettes in the 1950s.

Although tobacco is federally legal, it is considered to be more harmful than cannabis and known to cause health issues, including heart and lung disease, cancer, stroke, diabetes and chronic obstructive pulmonary disease. In fact, one of the reasons cannabis smokers have eclipsed cigarette smokers is that as people are becoming more cognizant of the health effects of smoking cigarettes, more are quitting and fewer are picking the habit up.

The CDC estimates that the number of “active” smokers in America has gone down from 20.9% in 2005 to 12.5% in 2020. Furthermore, the July Gallup poll found that three in 10 nonsmokers used to smoke cigarettes, representing a 30% drop in the Americans who smoke tobacco cigarettes. Ultimately, the number of people who are quitting cigarettes has even eclipsed those who are taking up cannabis, the poll found.

Writing for Gallup, Dr. Frank Newport said it is clear that cigarette use is declining and will become less prevalent as time passes. He touted increased public awareness of the negative health effects of smoking cigarettes as well as ongoing government efforts to curb cigarette use as major reasons behind the decline in smoking. Newport also noted that plenty of states now ban public smoking, making the habit more of an inconvenience than a luxury.

As more people learn about the benefits of marijuana, established entities such as Cannabis Strategic Ventures Inc. (OTC: NUGS) could find themselves with a much bigger client base to serve in the years to come.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.